Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4400 Biscayne Blvd. MIAMI FL 33137 |
Tel: | 1-310-6917100 |
Website: | https://www.opko.com |
IR: | See website |
Key People | ||
Phillip Frost Chairman of the Board, Chief Executive Officer | Elias A. Zerhouni President, Vice Chairman of the Board | Jane H. Hsiao Vice Chairman of the Board, Chief Technical Officer |
Adam E. Logal Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer | Charles W. Bishop Chief Executive Officer of OPKO Renal | Tony F. Cruz Chief Executive Officer, Transition Therapeutics, Inc |
Steven D. Rubin Executive Vice President - Administration, Director | Gary J. Nabel Chief Innovation Officer, Director |
Business Overview |
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company focuses on leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. Its segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and its pharmaceutical research and development. The diagnostics segment primarily consists of point-of-care operations. Its pharmaceutical business features Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage three or four chronic kidney disease (CKD) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. Its NGENLA (somatrogon-ghla), is a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older. |
Financial Overview |
For the six months ended 30 June 2024, OPKO Health Inc revenues decreased 29% to $355.9M. Net loss increased from $37.9M to $92.1M. Revenues reflect Pharmaceutical segment decrease of 78% to $52.8M, Diagnostics segment decrease of 1% to $256.3M, Ireland segment decrease of 83% to $19.1M, United States segment decrease of 14% to $277.8M, Israel segment decrease of 90% to $601K. |
Employees: | 3,930 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,179M as of Sep 30, 2024 |
Annual revenue (TTM): | $716.37M as of Sep 30, 2024 |
EBITDA (TTM): | -$164.27M as of Sep 30, 2024 |
Net annual income (TTM): | -$243.10M as of Sep 30, 2024 |
Free cash flow (TTM): | -$86.07M as of Sep 30, 2024 |
Net Debt Last Fiscal Year: | $167.63M as of Sep 30, 2024 |
Shares outstanding: | 697,376,055 as of Aug 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |